Acta otorrinolaringologica espanola · 2026
Intratympanic steroid for residual dizziness after benign paroxysmal positional vertigo: a randomized controlled study.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dogan Remzi, Polat Emre, Senturk Erol, Yenigun Alper, Eren Sabri Baki, Aksoy Fadlullah, Kucuk Ramazan Bahadir, Ozturan Orhan
Аннотация
OBJECTIVE: This study investigates the effectiveness of intratympanic steroid treatment in managing residual dizziness after benign paroxysmal positional vertigo (BPPV) and its impact on quality of life.
METHODS: Fifty-six patients with unilateral posterior canal BPPV without nystagmus after the Epley maneuver were randomized into two groups. Group 1 received intratympanic steroids (two sessions) with the canalith repositioning maneuver, while Group 2 received only the maneuver. Patients were assessed using the Dizziness Handicap Inventory (DHI), Visual Analog Scale (VAS), and residual dizziness evaluation on Day 1 and Day 10.
RESULTS: Baseline assessments showed no significant differences between groups. On Day 10, Group 1 showed significantly greater improvement in residual dizziness (p = 0.036) and Physical DHI scores (p = 0.047), while other DHI and VAS scores remained similar.
CONCLUSION: This study is the first to show that intratympanic steroids significantly reduce residual dizziness, potentially accelerating recovery and improving quality of life in BPPV patients.
METHODS: Fifty-six patients with unilateral posterior canal BPPV without nystagmus after the Epley maneuver were randomized into two groups. Group 1 received intratympanic steroids (two sessions) with the canalith repositioning maneuver, while Group 2 received only the maneuver. Patients were assessed using the Dizziness Handicap Inventory (DHI), Visual Analog Scale (VAS), and residual dizziness evaluation on Day 1 and Day 10.
RESULTS: Baseline assessments showed no significant differences between groups. On Day 10, Group 1 showed significantly greater improvement in residual dizziness (p = 0.036) and Physical DHI scores (p = 0.047), while other DHI and VAS scores remained similar.
CONCLUSION: This study is the first to show that intratympanic steroids significantly reduce residual dizziness, potentially accelerating recovery and improving quality of life in BPPV patients.